Caryn McDowell

Caryn McDowell is a Board Member and C-Level Executive with 20+ year of leadership in public biotech companies. She has served as Chief Legal Officer and Corporate Secretary at pre-clinical, development, and commercial-stage public companies in multiple therapeutic areas during pivotal inflection points including M&A, data readouts, NDA/BLA filings, and product launches. She has deep expertise leading companies from Phase 2 development through commercialization and successful exits. She has contributed to the successful launches of more than 10 drugs in her career and has played a key role in building corporate infrastructure and providing strategies crucial for a company’s first drug launch.

Ms. McDowell has significant risk management and corporate governance experience from more than seven years in the boardroom managing complex matters including M&A, securities litigation, whistleblowers, high-profile independent investigations, cybersecurity attacks, shareholder activism and drug recalls. She has led transformative strategic transactions including M&A, licensing and global collaborations. She has raised more than $800M in capital and has assisted with two sell side acquisitions worth approximately $18B to shareholders.

At Quince Therapeutics, a development-stage public biopharma company, Ms. McDowell has a broad operational role driving legal, compliance, human resources, IT, facilities and corporate governance. Previously, Ms. McDowell was SVP, General Counsel and Corporate Secretary at Revance Therapeutics. Other industry experience includes GC and Chief Compliance Officer at Cytokinetics, Inc. as well as VP, Deputy General Counsel at InterMune, Inc., where she was instrumental to the approval and launch of Esbriet® (pirfenidone) and acquisition by Roche for $8.8B. Ms. McDowell served in roles of increasing responsibility at Genentech, Onyx Pharmaceuticals, Affymax and Millennium Pharmaceuticals.

Prior to industry, Ms. McDowell served as a state and federal prosecutor at the Attorney General’s Office of the Commonwealth of Massachusetts and the Office of the Inspector General of HHS. She led investigations into Medicaid fraud, opioid drug diversion and drug pricing and reimbursement matters.

Ms. McDowell is a Board Member of the California Life Sciences and serves on the Policy & Advocacy Committee. She is on the Silicon Valley Board of Advisors of How Women Lead and is a founding LP partner of the How Women Invest $10M fund. She holds a J.D. degree from Boston University School of Law and a Bachelor of Arts from the University of Michigan.